S&P 500   3,967.05 (+0.09%)
DOW   33,760.41 (-0.06%)
QQQ   284.37 (+0.18%)
AAPL   143.04 (+0.27%)
MSFT   246.31 (-0.44%)
META   115.49 (+0.14%)
GOOGL   93.95 (+0.26%)
AMZN   89.61 (-0.82%)
TSLA   180.66 (+4.16%)
NVDA   174.26 (+1.50%)
NIO   13.00 (-3.06%)
BABA   93.14 (-1.09%)
AMD   69.89 (-0.82%)
T   19.24 (+0.63%)
MU   55.43 (+0.42%)
CGC   3.10 (+0.32%)
F   13.27 (+1.14%)
GE   82.36 (-1.52%)
DIS   94.03 (+1.60%)
AMC   6.05 (-0.33%)
PYPL   74.11 (-0.15%)
PFE   52.01 (+0.44%)
NFLX   325.44 (+4.89%)
S&P 500   3,967.05 (+0.09%)
DOW   33,760.41 (-0.06%)
QQQ   284.37 (+0.18%)
AAPL   143.04 (+0.27%)
MSFT   246.31 (-0.44%)
META   115.49 (+0.14%)
GOOGL   93.95 (+0.26%)
AMZN   89.61 (-0.82%)
TSLA   180.66 (+4.16%)
NVDA   174.26 (+1.50%)
NIO   13.00 (-3.06%)
BABA   93.14 (-1.09%)
AMD   69.89 (-0.82%)
T   19.24 (+0.63%)
MU   55.43 (+0.42%)
CGC   3.10 (+0.32%)
F   13.27 (+1.14%)
GE   82.36 (-1.52%)
DIS   94.03 (+1.60%)
AMC   6.05 (-0.33%)
PYPL   74.11 (-0.15%)
PFE   52.01 (+0.44%)
NFLX   325.44 (+4.89%)
S&P 500   3,967.05 (+0.09%)
DOW   33,760.41 (-0.06%)
QQQ   284.37 (+0.18%)
AAPL   143.04 (+0.27%)
MSFT   246.31 (-0.44%)
META   115.49 (+0.14%)
GOOGL   93.95 (+0.26%)
AMZN   89.61 (-0.82%)
TSLA   180.66 (+4.16%)
NVDA   174.26 (+1.50%)
NIO   13.00 (-3.06%)
BABA   93.14 (-1.09%)
AMD   69.89 (-0.82%)
T   19.24 (+0.63%)
MU   55.43 (+0.42%)
CGC   3.10 (+0.32%)
F   13.27 (+1.14%)
GE   82.36 (-1.52%)
DIS   94.03 (+1.60%)
AMC   6.05 (-0.33%)
PYPL   74.11 (-0.15%)
PFE   52.01 (+0.44%)
NFLX   325.44 (+4.89%)
S&P 500   3,967.05 (+0.09%)
DOW   33,760.41 (-0.06%)
QQQ   284.37 (+0.18%)
AAPL   143.04 (+0.27%)
MSFT   246.31 (-0.44%)
META   115.49 (+0.14%)
GOOGL   93.95 (+0.26%)
AMZN   89.61 (-0.82%)
TSLA   180.66 (+4.16%)
NVDA   174.26 (+1.50%)
NIO   13.00 (-3.06%)
BABA   93.14 (-1.09%)
AMD   69.89 (-0.82%)
T   19.24 (+0.63%)
MU   55.43 (+0.42%)
CGC   3.10 (+0.32%)
F   13.27 (+1.14%)
GE   82.36 (-1.52%)
DIS   94.03 (+1.60%)
AMC   6.05 (-0.33%)
PYPL   74.11 (-0.15%)
PFE   52.01 (+0.44%)
NFLX   325.44 (+4.89%)
NASDAQ:IMMP

Immutep - IMMP Stock Forecast, Price & News

$2.33
-0.03 (-1.27%)
(As of 12/9/2022 10:24 AM ET)
Add
Compare
Today's Range
$2.33
$2.34
50-Day Range
$1.56
$2.53
52-Week Range
$1.47
$3.64
Volume
92 shs
Average Volume
126,979 shs
Market Capitalization
$204.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IMMP stock logo

About Immutep (NASDAQ:IMMP) Stock

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemo-immunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia.

Receive IMMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immutep and its competitors with MarketBeat's FREE daily newsletter.

IMMP Stock News Headlines

Immutep to Participate in Two Upcoming Investor Conferences
Immutep Appoints LAG-3 Pioneer, Frédéric Triebel to Board
See More Headlines
Receive IMMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immutep and its competitors with MarketBeat's FREE daily newsletter.

IMMP Company Calendar

Today
12/09/2022
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMMP
Employees
2,021
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$4.90 million
Book Value
$0.79 per share

Miscellaneous

Free Float
85,210,000
Market Cap
$204.83 million
Optionable
Not Optionable
Beta
2.29

Key Executives

  • Mr. Marc Voigt (Age 49)
    CEO, MD, CFO, Chief Bus. Officer & Exec. Director
    Comp: $343.91k
  • Ms. Deanne Miller LLB (Age 45)
    COO, Gen. Counsel & Joint Company Sec.
    Comp: $231.28k
  • Dr. Frederic Triebel M.D. (Age 67)
    Ph.D., Chief Scientific Officer, Chief Medical Officer & Exec. Director
    Comp: $263.74k
  • Ms. Indira Naidu
    Joint Company Sec.
  • Mr. Christian Mueller
    Director of Clinical Devel. & Regulatory Affairs
  • Mr. Shengfei Fang
    Fin. Director & Assistant Company Sec.













IMMP Stock - Frequently Asked Questions

How have IMMP shares performed in 2022?

Immutep's stock was trading at $3.28 at the beginning of the year. Since then, IMMP shares have decreased by 28.0% and is now trading at $2.36.
View the best growth stocks for 2022 here
.

What other stocks do shareholders of Immutep own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immutep investors own include Nuwellis (CHFS), MEI Pharma (MEIP), VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), Gilead Sciences (GILD), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Vascular Biogenics (VBLT).

What is Immutep's stock symbol?

Immutep trades on the NASDAQ under the ticker symbol "IMMP."

Who are Immutep's major shareholders?

Immutep's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (0.59%), Dimensional Fund Advisors LP (0.08%), Balyasny Asset Management LLC (0.04%), Citadel Advisors LLC (0.00%) and Group One Trading L.P. (0.00%).

How do I buy shares of Immutep?

Shares of IMMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immutep's stock price today?

One share of IMMP stock can currently be purchased for approximately $2.36.

How much money does Immutep make?

Immutep (NASDAQ:IMMP) has a market capitalization of $207.47 million and generates $4.90 million in revenue each year.

How many employees does Immutep have?

The company employs 2,021 workers across the globe.

How can I contact Immutep?

Immutep's mailing address is LEVEL 12 95 PITT STREET, SYDNEY C3, 2000. The official website for the company is www.immutep.com. The biotechnology company can be reached via phone at (128) 315-7003, via email at jay.campbell@immutep.com, or via fax at 61-2-8569-1880.

This page (NASDAQ:IMMP) was last updated on 12/9/2022 by MarketBeat.com Staff